Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
Advanced Solid Tumors
BIOLOGICAL: mRNA-4359|BIOLOGICAL: Pembrolizumab
Number of Participants with Dose Limiting Toxicities (DLTs), Days 1-21 (Cycle 1)|Number of Participants with Adverse Events (AEs), AE of Special Interest (AESIs), and Serious AEs (SAEs), Up to 34 months
Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Day 1 up to approximately 27 months after the last dose of study treatment (duration of study treatment is up to nine 21-day cycles), or until disease progression, whichever occurs first|Disease Control Rate (DCR) Based on RECIST v1.1, Day 1 up to approximately 27 months after the last dose of study treatment (duration of study treatment is up to nine 21-day cycles), or until disease progression, whichever occurs first|Duration of Response (DOR) Based on RECIST v1.1, Day 1 up to approximately 27 months after the last dose of study treatment (duration of study treatment is up to nine 21-day cycles), or until disease progression, whichever occurs first|Progression Free Survival (PFS) Based on RECIST v1.1, Day 1 up to approximately 27 months after the last dose of study treatment (duration of study treatment is up to nine 21-day cycles), or until disease progression, whichever occurs first|Percent Change from Baseline in T Cell Profile in the Periphery and in the Tumor, Changes in CD3+CD8+, CD3+CD4+ and CD3+CD4+Foxp3+ cells will be measured by flow cytometry in peripheral blood and by immunohistochemistry in tumor., Day 1 up to approximately 27 months after the last dose of study treatment (duration of study treatment is up to nine 21-day cycles), or until disease progression, whichever occurs first
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.